Search Results - "SINHA, Vikram P"

Response to Comment on: Bergenstal et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012;35:2140-2147 by Bergenstal, Richard M, Rosenstock, Julio, Arakaki, Richard F, Prince, Melvin J, Qu, Yongming, Sinha, Vikram P, Howey, Daniel C, Jacober, Scott J

Get full text

Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism by MOORE, Mary Courtney, SMITH, Marta S, SINHA, Vikram P, BEALS, John M, MICHAEL, M. Dodson, JACOBER, Scott J, CHERRINGTON, Alan D

“…The impact of the novel basal insulin LY2605541 (LY) on hepatic and nonhepatic glucose uptake (non-HGU) was evaluated. Conscious dogs underwent euglycemic…”
Get full text

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin―Treated Patients With Type 2 Diabetes by BERGENSTAL, Richard M, ROSENSTOCK, Julio, ARAKAKI, Richard F, PRINCE, Melvin J, YONGMING QU, SINHA, Vikram P, HOWEY, Daniel C, JACOBER, Scott J

“…To evaluate whether LY2605541 results in lower fasting blood glucose (FBG) versus insulin glargine (GL). This 12-week, randomized, open-label, Phase 2 study…”
Get full text

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study by ROSENSTOCK, Julio, BERGENSTAL, Richard M, BLEVINS, Thomas C, MORROW, Linda A, PRINCE, Melvin J, YONGMING QU, SINHA, Vikram P, HOWEY, Daniel C, JACOBER, Scott J

“…OBJECTIVE To compare effects of LY2605541 versus insulin glargine on daily mean blood glucose as part of a basal-bolus regimen for type 1 diabetes. RESEARCH…”
Get full text

Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects by HENRY, Robert R, MUDALIAR, Sunder, CHEN QUIN LAM, Eric, PRINCE, Melvin J, BOSE, Namrata, PORKSEN, Niels, SINHA, Vikram P, LINNEBJERG, Helle, CIARALDI, Theodore P, ARMSTRONG, Debra A, BURKE, Paivi, PETTUS, Jeremy, GARHYAN, Parag, SIAK LENG CHOI, JACOBER, Scott J, KNADLER, Mary Pat

“…We evaluated the endogenous glucose production (EGP) and glucose disposal rate (GDR) over a range of doses of basal insulin peglispro (BIL) and insulin…”
Get full text

Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects by Sinha, Vikram P., Choi, Siak Leng, Soon, Danny Kwang Wei, Mace, Kenneth F., Yeo, Kwee Poo, Lim, Shufen T. H., Howey, Daniel C.

“…LY2605541 is a novel basal insulin analog with a prolonged duration of action. Two Phase I studies assessed LY2605541 pharmacokinetics (PK), glucodynamics…”
Get full text

Clinical Pharmacokinetics of Alamifovir and Its Metabolites by CHAN, Clark, ABU-RADDAD, Eyas, WISE, Stephen D, GOLOR, Georg, WATANABE, Hikari, SASAKI, Akira, KWEE POO YEO, SOON, Danny, SINHA, Vikram P, FLANAGAN, Shawn D, HE, Minxia M

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model by Schneck, Karen B., Zhang, Xin, Bauer, Robert, Karlsson, Mats O., Sinha, Vikram P.

“…A proof of concept study was conducted to investigate the safety and tolerability of a novel oral glucokinase activator, LY2599506, during multiple dose…”
Get full text

Pharmacokinetics of the Long-Acting Basal Insulin LY2605541 in Subjects With Varying Degrees of Renal Function by Linnebjerg, Helle, Choi, Siak Leng, Lam, Eric Chen Quin, Mace, Kenneth F., Hodgson, Teri S., Sinha, Vikram P.

“…The pharmacokinetics of LY2605541 (basal insulin peglispro), a novel long‐acting basal insulin analogue, was evaluated in 5 groups of subjects with varying…”
Get full text

Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug–drug interaction trials by Gueorguieva, Ivelina, Jackson, Kimberley, Wrighton, Steven A., Sinha, Vikram P., Chien, Jenny Y.

“…WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Desipramine is extensively metabolized by CYP2D6 to its main metabolite 2‐OH‐desipramine. • Alternative metabolic…”
Get full text

Safety, Tolerability, QTc Evaluation, and Pharmacokinetics of Single and Multiple Doses of Enzastaurin HCl (LY317615), a Protein Kinase C-β Inhibitor, in Healthy Subjects by Welch, Pamela A., Sinha, Vikram P., Cleverly, Ann L., Darstein, Christelle, Flanagan, Shawn D., Musib, Luna C.

“…The safety, tolerability, and pharmacokinetics of orally administered enzastaurin were evaluated in 2 placebo‐controlled, dose escalation studies in healthy…”
Get full text

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes by Rosenstock, Julio, Bergenstal, Richard M., Blevins, Thomas C., Morrow, Linda A., Prince, Melvin J., Qu, Yongming, Sinha, Vikram P., Howey, Daniel C., Jacober, Scott J.

“…OBJECTIVE To compare effects of LY2605541 versus insulin glargine on daily mean blood glucose as part of a basal-bolus regimen for type 1 diabetes. RESEARCH…”
Get full text

Safety, Tolerability, QTc Evaluation, and Pharmacokinetics of Single and Multiple Doses of Enzastaurin HCl (LY317615), a Protein Kinase C-{szligbeta} Inhibitor, in Healthy Subjects by Welch, Pamela A, Sinha, Vikram P, Cleverly, Ann L, Darstein, Christelle, Flanagan, Shawn D, Musib, Luna C

“…The safety, tolerability, and pharmacokinetics of orally administered enzastaurin were evaluated in 2 placebo-controlled, dose escalation studies in healthy…”
Get full text